The Role of Alarmins in Breast Cancer
DOI:
https://doi.org/10.54097/30f8ej75Keywords:
Alarmins, Hmgb1, S100A8, S100A9, IL-33, Breast CancerAbstract
Breast cancer (BC) remains the most common malignant tumor in women globally, with its incidence and mortality ranking first and second among female cancers, respectively. Despite continuous innovation and progress in modern medicine, current clinical treatment strategies for breast cancer still face high mortality rates. Therefore, developing new therapeutic targets and strategies is urgently needed. Alarmins are a class of endogenous molecules released during non-programmed cell death (such as infection or injury), and they typically serve as early warning signals for the immune system. Early research primarily focused on the role of alarmins in autoimmune and immune-mediated diseases, but recent studies have shown that alarmins also play a crucial role in the development, progression, and therapeutic response of breast cancer. In this review, we will discuss the role of alarmin family members (such as HMGB1, S100A8, S100A9, and IL-33) in breast cancer and their potential as therapeutic targets.
Downloads
References
[1] Siegel R L, Giaquinto A N, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49.
[2] Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview[J]. Cancers, 2014, 6(3): 1769-1792.
[3] Murao A, Aziz M, Wang H, et al. Release mechanisms of major DAMPs[J]. Apoptosis, 2021, 26(3-4): 152-162.
[4] Oppenheim J J, Yang D. Alarmins: chemotactic activators of immune responses[J]. Curr Opin Immunol, 2005, 17(4): 359-365.
[5] Nie Y, Yang D, Oppenheim J J. Alarmins and Antitumor Immunity[J]. Clin Ther, 2016, 38(5): 1042-1053.
[6] Sun S, Zhang W, Cui Z, et al. High mobility group box-1 and its clinical value in breast cancer[J]. Onco Targets Ther, 2015, 8: 413-419.
[7] Ni P, Zhang Y, Liu Y, et al. HMGB1 silence could promote MCF-7 cell apoptosis and inhibit invasion and metastasis[J]. Int J Clin Exp Pathol, 2015, 8(12): 15940-15946.
[8] Wang L L, Meng Q H, Jiao Y, et al. High-mobility group boxes mediate cell proliferation and radiosensitivity via retinoblastoma-interaction-dependent and -independent mechanisms[J]. Cancer Biother Radiopharm, 2012, 27(5): 329-335.
[9] Zhang Y L, Deng L, Liao L, et al. Chromatin complexes subunit BAP18 promotes triple-negative breast cancer progression through transcriptional activation of oncogene S100A9[J]. Cell Death Dis, 2022, 13(4): 408.
[10] Kim J Y, Kim G, Lim S C, Choi H S. IL-33-Induced Transcriptional Activation of LPIN1 Accelerates Breast Tumorigenesis[J]. Cancers (Basel), 2021, 13(9).
[11] Wang C Q, Huang B F, Wang Y, et al. [Expression of HMGB1 protein in breast cancer and its clinicopathological significance][J]. Zhonghua Bing Li Xue Za Zhi, 2020, 49(1): 57-61.
[12] Shi Q, Wang Y, Dong W, et al. Polychlorinated biphenyl quinone-induced signaling transition from autophagy to apoptosis is regulated by HMGB1 and p53 in human hepatoma HepG2 cells[J]. Toxicol Lett, 2019, 306: 25-34.
[13] Liang W J, Yang H W, Liu H N, et al. HMGB1 upregulates NF-kB by inhibiting IKB-α and associates with diabetic retinopathy[J]. Life Sci, 2020, 241: 117146.
[14] Stros M. HMGB proteins: interactions with DNA and chromatin[J]. Biochim Biophys Acta, 2010, 1799(1-2): 101-113.
[15] Andrews A J, Luger K. Nucleosome structure(s) and stability: variations on a theme[J]. Annu Rev Biophys, 2011, 40: 99-117.
[16] Yuan F, Gu L, Guo S, et al. Evidence for involvement of HMGB1 protein in human DNA mismatch repair[J]. J Biol Chem, 2004, 279(20): 20935-20940.
[17] Xu T, Jiang L, Wang Z. The progression of HMGB1-induced autophagy in cancer biology[J]. Onco Targets Ther, 2019, 12: 365-377.
[18] Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease[J]. Mol Aspects Med, 2014, 40: 1-116.
[19] Liu G, Wang J, Park Y J, et al. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine[J]. J Immunol, 2008, 181(6): 4240-4246.
[20] Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity[J]. Curr Opin Immunol, 2008, 20(5): 518-523.
[21] Srikrishna G, Freeze H H. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer[J]. Neoplasia, 2009, 11(7): 615-628.
[22] Su Q, Wang X, Zhu R, et al. Neoadjuvant chemotherapy reduces the levels of HMGB1 and E-cadherin in patients with breast cancer[J]. Sci Rep, 2023, 13(1): 14791.
[23] Wang L, Kang F B, Wang J, et al. Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway[J]. Anticancer Drugs, 2019, 30(3): 225-232.
[24] Ai H, Zhou W, Wang Z, et al. microRNAs-107 inhibited autophagy, proliferation, and migration of breast cancer cells by targeting HMGB1[J]. J Cell Biochem, 2019, 120(5): 8696-8705.
[25] Luo J, Chen J, He L. mir-129-5p Attenuates Irradiation-Induced Autophagy and Decreases Radioresistance of Breast Cancer Cells by Targeting HMGB1[J]. Med Sci Monit, 2015, 21: 4122-4129.
[26] Shi Y, Gong W, Lu L, et al. Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells[J]. Braz J Med Biol Res, 2019, 52(11): e8657.
[27] Chang B P, Wang D S, Xing J W, et al. miR-200c inhibits metastasis of breast cancer cells by targeting HMGB1[J]. J Huazhong Univ Sci Technolog Med Sci, 2014, 34(2): 201-206.
[28] Degryse B, Bonaldi T, Scaffidi P, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells[J]. J Cell Biol, 2001, 152(6): 1197-1206.
[29] El Gazzar M. HMGB1 modulates inflammatory responses in LPS-activated macrophages[J]. Inflammation Research, 2007, 56: 162-167.
[30] Li W, Xu Q, Deng Y, et al. High-mobility group box 1 accelerates lipopolysaccharide-induced lung fibroblast proliferation in vitro: involvement of the NF-κB signaling pathway[J]. Lab Invest, 2015, 95(6): 635-647.
[31] Jiao Y, Wang H C, Fan S J. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer[J]. Acta Pharmacol Sin, 2007, 28(12): 1957-1967.
[32] He H, Wang X, Chen J, et al. High-mobility group box 1 (HMGB1) promotes angiogenesis and tumor migration by regulating hypoxia-inducible factor 1 (HIF-1α) expression via the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway in breast cancer cells[J]. Medical science monitor: international medical journal of experimental and clinical research, 2019, 25: 2352.
[33] Jiao D, Zhang J, Chen P, et al. HN1L promotes migration and invasion of breast cancer by up-regulating the expression of HMGB1[J]. J Cell Mol Med, 2021, 25(1): 397-410.
[34] Chen Z G, Zhao H J, Lin L, et al. Circular RNA CirCHIPK3 promotes cell proliferation and invasion of breast cancer by sponging miR-193a/HMGB1/PI3K/AKT axis[J]. Thorac Cancer, 2020, 11(9): 2660-2671.
[35] Ananthula S, Sinha A, El Gassim M, et al. Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers[J]. Oncotarget, 2016, 7(15): 20869-20889.
[36] Sami E, Bogan D, Molinolo A, et al. The molecular underpinning of geminin-overexpressing triple-negative breast cancer cells homing specifically to lungs[J]. Cancer Gene Ther, 2022, 29(3-4): 304-325.
[37] Sundara Rajan S, Hanby A M, Horgan K, et al. The potential utility of geminin as a predictive biomarker in breast cancer[J]. Breast Cancer Res Treat, 2014, 143(1): 91-98.
[38] Blanchard Z, Mullins N, Ellipeddi P, et al. Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative[J]. PLoS One, 2014, 9(4): e95663.
[39] Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy[J]. Immunol Rev, 2007, 220: 47-59.
[40] Liu B, Qi X, Zhang X, et al. Med19 is involved in chemoresistance by mediating autophagy through HMGB1 in breast cancer[J]. J Cell Biochem, 2019, 120(1): 507-518.
[41] Curtin J F, Liu N, Candolfi M, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression[J]. PLoS Med, 2009, 6(1): e10.
[42] Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy[J]. Nat Med, 2007, 13(9): 1050-1059.
[43] Guerriero J L, Ditsworth D, Catanzaro J M, et al. DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity[J]. J Immunol, 2011, 186(6): 3517-3526.
[44] Stoetzer O J, Fersching D M, Salat C, et al. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy[J]. Tumour Biol, 2013, 34(1): 81-90.
[45] Ricci M S, Zong W X. Chemotherapeutic approaches for targeting cell death pathways[J]. Oncologist, 2006, 11(4): 342-357.
[46] Liang L, Fu J, Wang S, et al. MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1[J]. Acta Pharm Sin B, 2020, 10(6): 1036-1046.
[47] Wang N, Yang B, Muhetaer G, et al. XIAOPI formula promotes breast cancer chemosensitivity via inhibiting CXCL1/HMGB1-mediated autophagy[J]. Biomed Pharmacother, 2019, 120: 109519.
[48] Zhang H, Wang J, Li J, et al. HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer[J]. Cancer Sci, 2021, 112(4): 1603-1613.
[49] Hashemi-Niasari F, Rabbani-Chadegani A, Razmi M, Fallah S. Synergy of theophylline reduces necrotic effect of berberine, induces cell cycle arrest and PARP, HMGB1, Bcl-2 family mediated apoptosis in MDA-MB-231 breast cancer cells[J]. Biomed Pharmacother, 2018, 106: 858-867.
[50] Rauf A, Abu-Izneid T, Khalil A A, et al. Berberine as a Potential Anticancer Agent: A Comprehensive Review[J]. Molecules, 2021, 26(23).
[51] Rodríguez-Ruiz M E, Vanpouille-Box C, Melero I, et al. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect[J]. Trends Immunol, 2018, 39(8): 644-655.
[52] Zhu L, Hu S, Chen Q, et al. Macrophage contributes to radiation-induced anti-tumor abscopal effect on transplanted breast cancer by HMGB1/TNF-α signaling factors[J]. Int J Biol Sci, 2021, 17(4): 926-941.
[53] Fucikova J, Kepp O, Kasikova L, et al. Detection of immunogenic cell death and its relevance for cancer therapy[J]. Cell Death Dis, 2020, 11(11): 1013.
[54] [54] Hubert P, Roncarati P, Demoulin S, et al. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy[J]. J Immunother Cancer, 2021, 9(3).
[55] Wang X R, Zhou X H, Sun X T, et al. Tumour cell-released autophagosomes promote lung metastasis by upregulating PD-L1 expression in pulmonary vascular endothelial cells in breast cancer[J]. Cell Oncol (Dordr), 2024.
[56] Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease[J]. Arthritis Rheum, 2004, 50(12): 3762-3771.
[57] Salama I, Malone P S, Mihaimeed F, Jones J L. A review of the S100 proteins in cancer[J]. Eur J Surg Oncol, 2008, 34(4): 357-364.
[58] Heizmann C W, Fritz G, Schäfer B W. S100 proteins: structure, functions and pathology[J]. Front Biosci, 2002, 7: d1356-1368.
[59] Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles[J]. The international journal of biochemistry & cell biology, 2001, 33(7): 637-668.
[60] Lin C-R, Bahmed K, Criner G J, et al. S100A8 protects human primary alveolar type II cells against injury and emphysema[J]. American Journal of Respiratory Cell and Molecular Biology, 2019, 60(3): 299-307.
[61] Trøstrup H, Lerche C J, Christophersen L, et al. Immune Modulating Topical S100A8/A9 Inhibits Growth of Pseudomonas aeruginosa and Mitigates Biofilm Infection in Chronic Wounds[J]. Int J Mol Sci, 2017, 18(7).
[62] Cancemi P, Buttacavoli M, Di Cara G, et al. A multiomics analysis of S100 protein family in breast cancer[J]. Oncotarget, 2018, 9(49): 29064-29081.
[63] Allgöwer C, Kretz A L, Von Karstedt S, et al. Friend or Foe: S100 Proteins in Cancer[J]. Cancers (Basel), 2020, 12(8).
[64] Wang D, Liu G, Wu B, et al. Clinical Significance of Elevated S100A8 Expression in Breast Cancer Patients[J]. Front Oncol, 2018, 8: 496.
[65] Gonçalves A, Charafe-Jauffret E, Bertucci F, et al. Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes[J]. Mol Cell Proteomics, 2008, 7(8): 1420-1433.
[66] Choi D K, Li Z J, Chang I K, et al. Clinicopathological roles of S100A8 and S100A9 in cutaneous squamous cell carcinoma in vivo and in vitro[J]. Arch Dermatol Res, 2014, 306(5): 489-496.
[67] Wang S, Song R, Wang Z, et al. S100A8/A9 in Inflammation[J]. Frontiers in Immunology, 2018, 9: 1298.
[68] Singh P, Ali S A. Multifunctional Role of S100 Protein Family in the Immune System: An Update[J]. Cells, 2022, 11(15).
[69] Singh P, Ali S A. Impact of CRISPR-Cas9-Based Genome Engineering in Farm Animals[J]. Vet Sci, 2021, 8(7).
[70] Källberg E, Vogl T, Liberg D, et al. S100A9 interaction with TLR4 promotes tumor growth[J]. PLoS One, 2012, 7(3): e34207.
[71] Kaur H, Ali S A. Probiotics and gut microbiota: mechanistic insights into gut immune homeostasis through TLR pathway regulation[J]. Food Funct, 2022, 13(14): 7423-7447.
[72] Turovskaya O, Foell D, Sinha P, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis[J]. Carcinogenesis, 2008, 29(10): 2035-2043.
[73] Basso D, Bozzato D, Padoan A, et al. Inflammation and pancreatic cancer: molecular and functional interactions between S100A8, S100A9, NT-S100A8 and TGFβ1[J]. Cell Commun Signal, 2014, 12: 20.
[74] Zhong J M, Li J, Kang A D, et al. Protein S100-A8: A potential metastasis-associated protein for breast cancer determined via iTRAQ quantitative proteomic and clinicopathological analysis[J]. Oncol Lett, 2018, 15(4): 5285-5293.
[75] Singh P, Ali S A, Kumar S, Mohanty A K. CRISPR-Cas9 based knockout of S100A8 in mammary epithelial cells enhances cell proliferation and triggers oncogenic transformation via the PI3K-Akt pathway: Insights from a deep proteomic analysis[J]. J Proteomics, 2023, 288: 104981.
[76] Orimo A, Gupta P B, Sgroi D C, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion[J]. Cell, 2005, 121(3): 335-348.
[77] Soon P, Kim E, Pon C K, et al. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells[J]. Endocr Relat Cancer, 2013, 20(1): 1-12.
[78] Lim H, Koh M, Jin H, et al. Cancer-associated fibroblasts induce an aggressive phenotypic shift in non-malignant breast epithelial cells via interleukin-8 and S100A8[J]. J Cell Physiol, 2021, 236(10): 7014-7032.
[79] Miller P, Kidwell K M, Thomas D, et al. Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome[J]. Breast Cancer Res Treat, 2017, 166(1): 85-94.
[80] Li Y H, Liu H T, Xu J, et al. The value of detection of S100A8 and ASAH1 in predicting the chemotherapy response for breast cancer patients[J]. Hum Pathol, 2018, 74: 156-163.
[81] Wang Y, Guo A, Liang X, et al. HRD1 sensitizes breast cancer cells to Tamoxifen by promoting S100A8 degradation[J]. Oncotarget, 2017, 8(14): 23564-23574.
[82] Carlsson H, Petersson S, Enerbäck C. Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development[J]. International Journal of Oncology, 2005, 27(6): 1473-1481.
[83] Arai K, Teratani T, Kuruto-Niwa R, et al. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation[J]. European Journal of Cancer, 2004, 40(8): 1179-1187.
[84] Bao Y, Wang A, Mo J. S100A8/A9 is associated with estrogen receptor loss in breast cancer[J]. Oncology letters, 2016, 11(3): 1936-1942.
[85] Arai K, Teratani T, Kuruto-Niwa R, et al. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation[J]. Eur J Cancer, 2004, 40(8): 1179-1187.
[86] Arai K, Takano S, Teratani T, et al. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast[J]. Curr Cancer Drug Targets, 2008, 8(4): 243-252.
[87] Mckiernan E, Mcdermott E W, Evoy D, et al. The role of S100 genes in breast cancer progression[J]. Tumour Biol, 2011, 32(3): 441-450.
[88] Goh J Y, Feng M, Wang W, et al. Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence[J]. Nat Med, 2017, 23(11): 1319-1330.
[89] Powell A A, Talasaz A H, Zhang H, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines[J]. PLoS One, 2012, 7(5): e33788.
[90] Hsu Y L, Hung J Y, Tsai E M, et al. Benzyl butyl phthalate increases the chemoresistance to doxorubicin/ cyclophosphamide by increasing breast cancer-associated dendritic cell-derived CXCL1/GROα and S100A8/A9[J]. Oncol Rep, 2015, 34(6): 2889-2900.
[91] Bao Y I, Wang A, Mo J. S100A8/A9 is associated with estrogen receptor loss in breast cancer[J]. Oncol Lett, 2016, 11(3): 1936-1942.
[92] Zhang S, Wang Z, Liu W, et al. Distinct prognostic values of S100 mRNA expression in breast cancer[J]. Sci Rep, 2017, 7: 39786.
[93] Du X M, Chang H, Sun H Y, et al. [Expression and clinical significance of calcium-binding protein S100A9 in breast cancer][J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2012, 28(6): 637-639.
[94] Bertolini I, Perego M, Nefedova Y, et al. Intercellular hif1α reprograms mammary progenitors and myeloid immune evasion to drive high-risk breast lesions[J]. J Clin Invest, 2023, 133(8).
[95] Helfen A, Rieß J, Fehler O, et al. In vivo imaging of microenvironmental and anti-PD-L1-mediated dynamics in cancer using S100A8/S100A9 as an imaging biomarker[J]. Neoplasia, 2022, 28: 100792.
[96] Moon A, Yong H Y, Song J I, et al. Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion[J]. Mol Cancer Res, 2008, 6(10): 1544-1553.
[97] Chung Y H, Park J, Cai H, Steinmetz N F. S100A9-Targeted Cowpea Mosaic Virus as a Prophylactic and Therapeutic Immunotherapy against Metastatic Breast Cancer and Melanoma[J]. Adv Sci (Weinh), 2021, 8(21): e2101796.
[98] Gumireddy K, Li A, Kossenkov A V, et al. ID1 promotes breast cancer metastasis by S100A9 regulation[J]. Mol Cancer Res, 2014, 12(9): 1334-1343.
[99] Li J, Shu X, Xu J, et al. S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy[J]. Nat Commun, 2022, 13(1): 1481.
[100] Yang W S, Moon H G, Kim H S, et al. Proteomic approach reveals FKBP4 and S100A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer[J]. J Proteome Res, 2012, 11(2): 1078-1088.
[101] Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells[J]. The Journal of Immunology, 2008, 181(7): 4666-4675.
[102] Vogl T, Eisenblätter M, Völler T, et al. Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity[J]. Nature communications, 2014, 5(1): 4593.
[103] Khorrami S, Tavakoli M, Safari E. Clinical value of serum S100A8/A9 and CA15-3 in the diagnosis of breast cancer[J]. Iranian Journal of Pathology, 2019, 14(2): 104.
[104] Pruenster M, Vogl T, Roth J, Sperandio M. S100A8/A9: From basic science to clinical application[J]. Pharmacol Ther, 2016, 167: 120-131.
[105] Shabani F, Farasat A, Mahdavi M, Gheibi N. Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer[J]. Inflamm Res, 2018, 67(10): 801-812.
[106] Nasser M W, Ahirwar D K, Ganju R K. RAGE: A novel target for breast cancer growth and metastasis[J]. Oncoscience, 2016, 3(2): 52-53.
[107] Leanderson T, Ivars F. S100A9 and tumor growth[J]. Oncoimmunology, 2012, 1(8): 1404-1405.
[108] Otazu G K, Dayyani M, Badie B. Role of RAGE and Its Ligands on Inflammatory Responses to Brain Tumors[J]. Front Cell Neurosci, 2021, 15: 770472.
[109] Kwak T, Drews-Elger K, Ergonul A, et al. Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis[J]. Oncogene, 2017, 36(11): 1559-1572.
[110] Yin C, Li H, Zhang B, et al. RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial-mesenchymal transition[J]. Breast Cancer Res Treat, 2013, 142(2): 297-309.
[111] Rigiracciolo D C, Nohata N, Lappano R, et al. Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC)[J]. J Exp Clin Cancer Res, 2022, 41(1): 193.
[112] Chen Y, Sumardika I W, Tomonobu N, et al. Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness[J]. Neoplasia, 2019, 21(7): 627-640.
[113] Rodriguez-Barrueco R, Yu J, Saucedo-Cuevas L P, et al. Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers[J]. Genes Dev, 2015, 29(15): 1631-1648.
[114] Kearney M, Franks L, Lee S, et al. Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer[J]. Breast cancer research and treatment, 2021, 189(1): 177-185.
[115] Zamani P, Navashenaq J G, Teymouri M, et al. Combination therapy with liposomal doxorubicin and liposomal vaccine containing E75, an HER-2/neu-derived peptide, reduces myeloid-derived suppressor cells and improved tumor therapy[J]. Life sciences, 2020, 252: 117646.
[116] Deng Z, Rong Y, Teng Y, et al. Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis[J]. Oncogene, 2017, 36(5): 639-651.
[117] Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis[J]. Cell, 2012, 150(1): 165-178.
[118] Pichery M, Mirey E, Mercier P, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain[J]. J Immunol, 2012, 188(7): 3488-3495.
[119] Kakkar R, Hei H, Dobner S, Lee R T. Interleukin 33 as a mechanically responsive cytokine secreted by living cells[J]. J Biol Chem, 2012, 287(9): 6941-6948.
[120] Haenuki Y, Matsushita K, Futatsugi-Yumikura S, et al. A critical role of IL-33 in experimental allergic rhinitis[J]. J Allergy Clin Immunol, 2012, 130(1): 184-194.e111.
[121] Kouzaki H, Iijima K, Kobayashi T, et al. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses[J]. J Immunol, 2011, 186(7): 4375-4387.
[122] Moussion C, Ortega N, Girard J P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?[J]. PLoS One, 2008, 3(10): e3331.
[123] Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines[J]. Immunity, 2005, 23(5): 479-490.
[124] Liu X, Zhu L, Lu X, et al. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer[J]. Biochem Biophys Res Commun, 2014, 453(3): 486-492.
[125] Lu D P, Zhou X Y, Yao L T, et al. Serum soluble ST2 is associated with ER-positive breast cancer[J]. BMC Cancer, 2014, 14: 198.
[126] Hu L A, Fu Y, Zhang D N, Zhang J. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer[J]. Asian Pac J Cancer Prev, 2013, 14(4): 2563-2566.
[127] Kim J Y, Lim S C, Kim G, et al. Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity[J]. Oncogene, 2015, 34(38): 4928-4938.
[128] Sun P, Ben Q, Tu S, et al. Serum interleukin-33 levels in patients with gastric cancer[J]. Dig Dis Sci, 2011, 56(12): 3596-3601.
[129] Wang C, Chen Z, Bu X, et al. IL-33 signaling fuels outgrowth and metastasis of human lung cancer[J]. Biochem Biophys Res Commun, 2016, 479(3): 461-468.
[130] Zhang P, Liu X K, Chu Z, et al. Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications[J]. J Int Med Res, 2012, 40(5): 1654-1661.
[131] Rössle M, Cathomas G, Bonapace L, et al. Interleukin-33 Expression Indicates a Favorable Prognosis in Malignant Salivary Gland Tumors[J]. Int J Surg Pathol, 2016, 24(5): 394-400.
[132] Tong X, Barbour M, Hou K, et al. Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways[J]. Mol Oncol, 2016, 10(1): 113-125.
[133] Zhang J, Wang P, Ji W, et al. Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma[J]. Int J Neurosci, 2017, 127(3): 210-217.
[134] Feng X, Liu H, Chu X, et al. Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer[J]. Acta Biomater, 2019, 100: 316-325.
[135] Gao K, Li X, Zhang L, et al. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice[J]. Cancer Lett, 2013, 335(2): 463-471.
[136] Gao X, Wang X, Yang Q, et al. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells[J]. J Immunol, 2015, 194(1): 438-445.
[137] Griesenauer B, Paczesny S. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases[J]. Front Immunol, 2017, 8: 475.
[138] Jovanovic I, Radosavljevic G, Mitrovic M, et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma[J]. Eur J Immunol, 2011, 41(7): 1902-1912.
[139] Xiao P, Wan X, Cui B, et al. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells[J]. Oncoimmunology, 2016, 5(1): e1063772.
[140] Yang Z P, Ling D Y, Xie Y H, et al. The Association of Serum IL-33 and sST2 with Breast Cancer[J]. Dis Markers, 2015, 2015: 516895.
[141] Hollande C, Boussier J, Ziai J, et al. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth[J]. Nat Immunol, 2019, 20(3): 257-264.
[142] Yigitbasi M R, Guntas G, Atak T, et al. The Role of Interleukin-33 as an Inflammatory Marker in Differential Diagnosis of Idiopathic Granulomatous Mastitis and Breast Cancer[J]. J Invest Surg, 2017, 30(4): 272-276.
[143] Gorbacheva A M, Kuprash D V, Mitkin N A. [Regulation of IL33 Gene Expression by SP1 and Foxa1 in Breast and Lung Cancer Cells][J]. Mol Biol (Mosk), 2021, 55(1): 107-117.
[144] Hu H, Sun J, Wang C, et al. IL-33 facilitates endocrine resistance of breast cancer by inducing cancer stem cell properties[J]. Biochem Biophys Res Commun, 2017, 485(3): 643-650.Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview[J]. Cancers, 2014, 6(3): 1769-1792.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
